Echinocandins--first line in invasive candidiasis: how strong is this 'strong' evidence?
作者信息
Gonçalves-Pereira João, Póvoa Pedro
出版信息
Crit Care. 2011;15(6):461; author reply 461. doi: 10.1186/cc10580. Epub 2011 Dec 15.
Abstract
摘要
相似文献
1
Echinocandins--first line in invasive candidiasis: how strong is this 'strong' evidence?棘白菌素类——侵袭性念珠菌病的一线治疗药物：这种“有力”证据有多强？
Crit Care. 2011;15(6):461; author reply 461. doi: 10.1186/cc10580. Epub 2011 Dec 15.
2
Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.阿尼芬净与氟康唑治疗严重侵袭性念珠菌病（包括念珠菌血症）患者的比较：支持 2009IDSA 念珠菌病治疗指南。
Crit Care. 2011;15(5):R253. doi: 10.1186/cc10514. Epub 2011 Oct 25.
3
Treatment of invasive candidiasis: between guidelines and daily clinical practice.侵袭性念珠菌病的治疗：介于指南与日常临床实践之间
Expert Rev Anti Infect Ther. 2015 Jun;13(6):685-9. doi: 10.1586/14787210.2015.1029916. Epub 2015 Mar 27.
4
Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.白色念珠菌和非白色念珠菌引起的侵袭性念珠菌病初始治疗抗真菌疗法的药物经济学分析
BMC Infect Dis. 2017 Jul 10;17(1):481. doi: 10.1186/s12879-017-2573-8.
5
Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.棘白菌素类药物（阿尼芬净）与氟康唑治疗念珠菌血症和其他侵袭性念珠菌病的资源利用与治疗费用：关注重症患者。
Pharmacoeconomics. 2011 Aug;29(8):705-17. doi: 10.2165/11584810-000000000-00000.
6
Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.抗真菌药物降级治疗与接受侵袭性念珠菌病治疗的危重症患者的不良结局无关：AmarCAND2 研究数据的事后分析。
Intensive Care Med. 2015 Nov;41(11):1931-40. doi: 10.1007/s00134-015-4053-1. Epub 2015 Sep 14.
7
Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.安尼卡群（anidulafungin）与氟康唑治疗侵袭性念珠菌病的成本效益分析。
J Antimicrob Chemother. 2011 Aug;66(8):1906-15. doi: 10.1093/jac/dkr186. Epub 2011 May 30.
8
Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.阿尼芬净治疗念珠菌血症及其他侵袭性念珠菌病的成本效益分析。
BMC Infect Dis. 2015 Oct 26;15:463. doi: 10.1186/s12879-015-1143-1.
9
Candida tropicalis in human disease.热带假丝酵母菌与人类疾病。
Crit Rev Microbiol. 2010 Nov;36(4):282-98. doi: 10.3109/1040841X.2010.489506.
10
Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.侵袭性耳念珠菌感染治疗的药效学优化
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00791-17. Print 2017 Aug.
引用本文的文献
1
Comparative analysis of CRP as a biomarker of the inflammatory response intensity among common viral infections affecting the lungs: COVID-19 versus influenza A, influenza B and respiratory syncytial virus.比较分析 CRP 作为常见肺部病毒感染的炎症反应强度的生物标志物：COVID-19 与甲型流感、乙型流感和呼吸道合胞病毒。
Clin Exp Med. 2023 Dec;23(8):5307-5313. doi: 10.1007/s10238-023-01176-0. Epub 2023 Aug 28.
2
ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients.ESICM/ESCMID 工作组关于危重症患者侵袭性念珠菌感染的实际管理。
Intensive Care Med. 2019 Jun;45(6):789-805. doi: 10.1007/s00134-019-05599-w. Epub 2019 Mar 25.
本文引用的文献
1
Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.阿尼芬净与氟康唑治疗严重侵袭性念珠菌病（包括念珠菌血症）患者的比较：支持 2009IDSA 念珠菌病治疗指南。
Crit Care. 2011;15(5):R253. doi: 10.1186/cc10514. Epub 2011 Oct 25.
2
Treatment of candidemia in adult patients without neutropenia--an inconvenient truth.成人非中性粒细胞减少患者念珠菌血症的治疗——一个尴尬的事实。
Crit Care. 2011;15(1):114. doi: 10.1186/cc9414. Epub 2011 Jan 31.
3
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.念珠菌病管理临床实践指南：美国传染病学会2009年更新版
Clin Infect Dis. 2009 Mar 1;48(5):503-35. doi: 10.1086/596757.
4
Anidulafungin versus fluconazole for invasive candidiasis.阿尼芬净与氟康唑治疗侵袭性念珠菌病的比较
N Engl J Med. 2007 Jun 14;356(24):2472-82. doi: 10.1056/NEJMoa066906.
5
Lessons from and cautions about noninferiority and equivalence randomized trials.非劣效性和等效性随机试验的经验教训与注意事项。
JAMA. 2006 Mar 8;295(10):1172-4. doi: 10.1001/jama.295.10.1172.
6
Statistical issues in interpreting clinical trials.解读临床试验中的统计学问题。
J Intern Med. 2004 May;255(5):529-37. doi: 10.1111/j.1365-2796.2004.01320.x.
7
Echinocandins--an advance in the primary treatment of invasive candidiasis.棘白菌素类药物——侵袭性念珠菌病初始治疗的一项进展。
N Engl J Med. 2002 Dec 19;347(25):2070-2. doi: 10.1056/NEJMe020142.
8
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.念珠菌病治疗实践指南。美国传染病学会。
Clin Infect Dis. 2000 Apr;30(4):662-78. doi: 10.1086/313749. Epub 2000 Apr 20.
Zotero 插件